Clinical Study
Lower Viral Response to Pegylated Interferon Alpha 2a Treatment of Chronic Hepatitis B in Roma People in Eastern Slovakia
Table 4
HBV DNA during treatment and followup, real-world cohort.
| | Roma | Non-Roma | |
| M6 HBV DNA <2000 IU/mL | 30/43 | 69.8% | 38/46 | 82.6% | 0.154 | M6 HBV DNA negative | 3/43 | 7.0% | 7/46 | 15.2% | 0.318 | M12 HBV DNA <2000 IU/mL | 22/43 | 51.2% | 37/46 | 80.4% | 0.003 | M12 HBV DNA negative | 3/43 | 7.0% | 9/46 | 19.6% | 0.082 | M18 HBV DNA <2000 IU/mL | 13/43 | 30.2% | 19/46 | 41.3% | 0.277 | M18 HBV DNA negative | 0/43 | 0% | 3/46 | 6.5% | 0.242 |
|
|
M6: 6 months after the start of the treatment, M12: end of treatment, and M18: 6 months after the end of the treatment.
|